All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the 2021 ASCO Annual Meeting, the ALL Hub spoke with Jorge Cortes, Augusta University, Augusta, US. We asked, What are the main advances in patient care that we are seeing with novel agents for leukemia?
What are the main advances in patient care that we are seeing with novel agents for leukemia?
Cortes begins by outlining two practice-changing trials and their encouraging response rates. The first being the ZUMA-3 (utilizing CAR T-cell therapy), and the second investigating lintuzumab regimes in adult Philadelphia chromosome-positive ALL patients. He goes on to review two further studies investigating inotuzumab and the value of assessing MRD in patients.
Current recommendations for therapy-related toxicity management in ALL
Despite the great clinical advances in the field of acute lymphoblastic leukemia (ALL), novel therapies have led to the emergence of unique toxicities that need to be...
The current treatment landscape of acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a rare hematological disorder with a bimodal incidence in childhood and in older adults. The advent of multiple chemotherapies has drastically...
Subscribe to get the best content related to ALL delivered to your inbox